DocWire News Dr. Camidge Discusses Launch of Phase 2 Trial Evaluating RAF/MEK Inhibitor in NSCLC
Dr. Camidge Discusses Launch of Phase 2 Trial Evaluating RAF/MEK Inhibitor in NSCLC
13-Jan-21
OncLive RAF/MEK Inhibitor VS-6766 Plus Defactinib Under Exploration in Recurrent Low-Grade Serous Ovarian Cancer 6-Jan-21
Oncology Tube D. Ross Camidge, M.D., Ph.D @CUAnschutz @VerastemOncolog #NSCLC #RAMP202 #Cancer #Research Phase 2 Registration-Directed Trial of VS-6766 and Defactinib
D. Ross Camidge, M.D., Ph.D @CUAnschutz @VerastemOncolog #NSCLC #RAMP202 #Cancer #Research Phase 2 Registration-Directed Trial of VS-6766 and Defactinib
23-Dec-20
BioWorld In the clinic for Dec. 15, 2020 15-Dec-20
BioPharma Journal Verastem Oncology (NASDAQ:VSTM) Commence Phase 2 VS-6766 Study in Low-Grade Serous Ovarian Cancer Patients 9-Dec-20
DocWire News Drs. Banerji and Pachter Talk About RAF/MEK Inhibitor in RAS Mutant Tumors
Drs. Banerji and Pachter Talk About RAF/MEK Inhibitor in RAS Mutant Tumors
2-Dec-20
Pharma Premium Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer 30-Nov-20
Precision Oncology News Verastem Oncology Launches Phase II Trial of MEK, Pan-RAF Inhibitor in Ovarian Cancer 30-Nov-20
Oncology Tube Udai Banerji, MD @udai_banerji @IRC_London @royalmarsden @VerastemOncolog #KRASMutations #cancer #research VS-6766, a unique inhibitor of the RAF/MEK signaling pathway for patients
Udai Banerji, MD @udai_banerji @IRC_London @royalmarsden @VerastemOncolog #KRASMutations #cancer #research VS-6766, a unique inhibitor of the RAF/MEK signaling pathway for patients
6-Nov-20
Cancer Health KRAS Inhibitors Show Promise in Early Studies 5-Nov-20
Onco’Zine Investigator-Initiated Study Supports Potential of VS-6766 as Treatment for RAS Mutant Tumors 29-Oct-20